Nuzenio

Tradingview Syre

Tradingview Syre entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 8 latest news signals 1 publisher sources 100/100 entity strength

Latest news

Spyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside - TradingViewTradingView · Wed, 05 Aug 2026 17:20:17 GMTSpyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Tue, 04 Aug 2026 21:21:22 GMTSpyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026 - TradingViewTradingView · Tue, 04 Aug 2026 20:14:03 GMTSpyre Therapeutics reports $1.145B cash, Q2 net loss $36.2M; positive Phase 2 induction data - TradingViewTradingView · Tue, 04 Aug 2026 20:13:01 GMTSpyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary - TradingViewTradingView · Tue, 04 Aug 2026 20:11:01 GMTSYRE: Strong Phase 2 results and $1.15B cash position support continued clinical progress - TradingViewTradingView · Tue, 04 Aug 2026 20:06:58 GMTSYRE: Strong liquidity and key clinical milestones support ongoing R&D despite rising losses - TradingViewTradingView · Tue, 04 Aug 2026 20:04:13 GMTSYRE Q2'26 Earnings: revenue estimate is 0 USD - TradingViewTradingView · Thu, 30 Jul 2026 07:00:00 GMT

Timeline

Wed, 05 Aug 2026 17:20:17 GMTSpyre Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.43, Implies 14% Upside - TradingView
Tue, 04 Aug 2026 21:21:22 GMTSpyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary - TradingView
Tue, 04 Aug 2026 20:14:03 GMTSpyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026 - TradingView
Tue, 04 Aug 2026 20:13:01 GMTSpyre Therapeutics reports $1.145B cash, Q2 net loss $36.2M; positive Phase 2 induction data - TradingView
Tue, 04 Aug 2026 20:11:01 GMTSpyre Therapeutics, Inc. Q2 2026: Net loss $36.2M, EPS $(0.36) — 10-Q Summary - TradingView
Tue, 04 Aug 2026 20:06:58 GMTSYRE: Strong Phase 2 results and $1.15B cash position support continued clinical progress - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Syre.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.